NJ doctor loses license after hepatitis B outbreak

(AP) -- New Jersey officials have revoked the medical license of an oncologist they say committed "gross and repeated acts of negligence" that led to an outbreak of hepatitis B among his patients.

The Star-Ledger newspaper reports that the state Board of Medical Examiners on Wednesday revoked Parvez Dara's license for four years and charged him $30,000 in civil penalties. His license already had been suspended for 2 1/2 years, meaning he can reapply in 18 months.

Prosecutors said conditions at Dara's office were rife for spreading infections. They say at least 29 of his patients have been infected with , a virus that affects the liver.

Dara's lawyer, Peter Korn, said evidence that the cases of were linked was based on "flawed medical science."

The state had warned more than 5,000 patients at Dara's Toms River office to get tested.

0 shares

Related Stories

NJ: 29 hepatitis cases tied to 1 doctor's office

date Sep 09, 2009

(AP) -- Several thousand patients of a New Jersey doctor should get tested for blood-borne diseases because of an outbreak linked to his office that has led to more than two dozen being diagnosed with hepatitis B, state ...

'Octomom' doctor stripped of medical license

date Jun 02, 2011

The fertility doctor who helped a woman give birth to octuplets in 2009 will be stripped of his license by the California Medical Board because of "gross negligence."

Patients notified of HIV, hepatitis risk

date Nov 14, 2007

Officials have notified about 630 patients of a New York area physician who reused needles and syringes that they are at risk for HIV and hepatitis B and C.

Police raid Nevada clinics

date Mar 12, 2008

Authorities investigating a hepatitis outbreak have seized patient records from six southern Nevada medical offices.

Recommended for you

Cardinal Health paying $26.8 million in FTC settlement

date 8 hours ago

Cardinal Health will pay $26.8 million as part of a settlement with the Federal Trade Commission over charges it monopolized the sale in 25 markets of diagnostic drugs known as low-energy radiopharmaceuticals.

Selecting the right tool for the job

date Apr 14, 2015

Randomized clinical trials of new drugs have long been considered the "gold standard" in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.